Noradrenalin Kabi (Noradrenaline Tartrate)

Noradrenalin Kabi is a vasopressor used in conditions characterized by low systemic vascular resistance and hypotension.

• Acute hypotension: restores arterial pressure and organ perfusion in critically ill patients.
• Septic shock: counteracts vasodilatory shock to maintain hemodynamic stability.
• Post‑operative hypotension: supports blood pressure after surgery to prevent organ hypoperfusion.
• Cardiac arrest: provides immediate pressor support during resuscitation efforts.

• Noradrenalin tartrate acts as an alpha‑adrenergic agonist, primarily stimulating α1 receptors on vascular smooth muscle. This activation induces vasoconstriction, increasing systemic vascular resistance and raising arterial blood pressure. At higher concentrations it also stimulates β1 receptors, enhancing cardiac contractility and heart rate, which further contributes to hemodynamic support in shock states. The net effect rapidly improves perfusion to vital organs while reducing the risk of prolonged hypotension.

Noradrenalin Kabi may be associated with several adverse reactions, ranging from frequent to severe.

Common Side Effects

• Tachycardia: increased heart rate due to β1 stimulation.
• Headache: vascular constriction can trigger cranial discomfort.
• Nausea: gastrointestinal upset is occasionally reported.
• Peripheral ischemia: reduced blood flow to extremities may cause coldness or discoloration.

Serious or Rare Side Effects

• Myocardial ischemia: excessive coronary vasoconstriction can precipitate chest pain or infarction.
• Severe hypertension: abrupt rise in blood pressure may lead to cerebrovascular events.
• Tissue necrosis at infusion site: extravasation can cause local tissue damage requiring surgical intervention.

When using Noradrenalin Kabi, clinicians should observe specific safety measures to minimize risks.

• Monitor blood pressure continuously: adjust infusion rate to maintain target pressures.
• Adjust infusion rate based on response: titrate to the lowest effective dose.
• Use central venous access when possible: reduces risk of local tissue injury.
• Avoid rapid bolus administration: administer as a controlled infusion.
• Caution in patients with cardiac ischemia: monitor for chest pain or ECG changes.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Noradrenalin Kabi can interact with other agents, influencing its pressor effect or safety profile.

Major Interactions (Avoid)

• MAO inhibitors: may cause excessive hypertension.
• Beta‑blockers: can blunt the desired increase in heart rate and contractility.
• Other vasopressors: concurrent use may lead to severe vasoconstriction and organ ischemia.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may reduce the pressor response, requiring dose adjustments.
• Diuretics: can potentiate hypotensive episodes if the infusion is reduced abruptly.